Sector News

Amgen trims 172 more jobs, this time in operations, R&D and sales

November 20, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Amgen’s top line has suffered from knockoff competition in recent quarters, and now the pain is moving to its payroll. After disclosing almost 150 cuts on the East Coast last week, the biotech giant now says it’s cutting 172 staffers at its headquarters and in the field.

The layoffs will hit R&D, operations and commercial employees, Amgen said in a California WARN filing (PDF). The majority of the jobs targeted are field-based jobs throughout the U.S., though some cuts will hit its headquarters in Thousand Oaks, California.

The layoffs will take effect Dec. 31, the filing said.

An Amgen spokeswoman said the company, like others, “regularly evaluates and adjusts staffing levels to meet the needs of the business.”

“While these decisions are never easy, we believe our ability to compete will be strengthened by a tighter focus on investments that can help bring important medicines to patients to treat serious, life-threatening illnesses,” she added.

The cuts come as Amgen deals with patent expirations and new biosimilar rivals. The company faces generic versions of its thyroid drug Sensipar and recently launched copycats to its white blood cell boosters Neupogen and Neulasta—plus anemia drug Epogen. Biosimilar versions of its immunology med Enbrel are approved but not yet launched. Amgen defeated a patent challenge on Enbrel from Sandoz over the summer.

Thanks to new rivals, the drugmaker’s sales dipped 2% in the second quarter and 3% in the third quarter versus the same periods last year.

Meanwhile, as biosims take a toll on its drugs, the company is hitting back with its own biosimilars to other companies’ blockbusters—and those meds brought in $173 million last quarter.

Last week, Amgen said it’d cut 149 jobs in Massachusetts by the end of the year as it exits neuroscience R&D.

Amgen in 2014 laid off 2,900 employees in a major restructuring, and the company in 2017 cut jobs as part of a plan to shift employment to a new facility in Tampa.

By Eric Sagonowsky

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

December 5, 2019

Novartis taps Amazon know-how for ‘smart’ manufacturing, supply chain

Life sciences

LinkedIn Twitter FacebookNovartis has joined forces with Amazon, drawing on the online retail giant’s technological wizardry to reduce bottlenecks and improve the efficiency of its manufacturing and distribution. The deal […]

December 4, 2019

Horizon looks to the future with massive San Francisco manufacturing, R&D plant

Life sciences

LinkedIn Twitter FacebookHorizon Therapeutics, once known for its primary care drugs, is looking to pivot further to rare diseases with the FDA scrutinizing its late-stage inflammatory eye disease candidate. In […]

December 2, 2019

Could AI create a brave new world of pharma R&D?

Life sciences

LinkedIn Twitter FacebookArtificial Intelligence (AI) has become the latest buzz word in drug R&D, and many of the world’s biggest pharma companies claim to be using it to drive forward […]

Subscribe to our Weekly Newsletter

We're easy to reach